The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Bacterially Derived 400 nm Particles for Encapsulation and Cancer Cell Targeting of Chemotherapeutics
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 2×
“…arm recognizes the O-antigen component of the mini- cell surface LPS and the other, a cell-surface receptor specific for the mammalian cell to be targeted, for exam- ple, EGFR (El-Rayes and LoRusso, 2004) or HER2/neu re- ceptor (Slamon et al., 1987) on breast and ovarian cancer cells, respectively.”
BackgroundMethodAkira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
In vivo cancer targeting and imaging with semiconductor quantum dots
Gao, X., Cui, Y., Levenson, R. M., Chung, L. W. K., & Nie, S. (2004) · Nature Biotechnology · doi:10.1038/nbt994 · Cited by 4,772
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Molecular Basis of Bacterial Outer Membrane Permeability Revisited
Nikaido, H. (2003) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.67.4.593-656.2003 · Cited by 4,316 · cited 2×
“Drug loading of minicells is likely by diffusion down a concentration gradient with entry via nonspecific porin channels ( Nikaido, 1996, 2003; Poole, 2002) in the outer membrane.”
BackgroundThe dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Nanoparticle and targeted systems for cancer therapy
Brannon-Peppas, L., & Blanchette, J. O. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.014 · Cited by 2,334
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
(2016) · CRC Press eBooks · doi:10.1201/b12801 · Cited by 2,031
Cited by
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Nanoparticle-based targeted drug delivery
Singh, R., & Lillard, J. W. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.12.004 · Cited by 2,734
New trends for metal complexes with anticancer activity
Bruijnincx, P. C., & Sadler, P. J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.11.013 · Cited by 1,306
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M. J., Bailey, D. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30621-6 · Cited by 710
Self-citationRatti, M., Lampis, A., Ghidini, M., Salati, M., Mirchev, M. B., Valeri, N., & Hahne, J. C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00717-x · Cited by 606
Gujrati, V., Kim, S., Kim, S.-H., Min, J. J., Choy, H. E., Kim, S. C., & Jon, S. (2014) · ACS Nano · doi:10.1021/nn405724x · Cited by 543
MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance
Iqbal, M. A., Arora, S., Prakasam, G., Calin, G. A., & Syed, M. A. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.003 · Cited by 449
Receptor-targeted nanocarriers for therapeutic delivery to cancer
Yu, B., Tai, H. C., Xue, W., Lee, L. J., & Lee, R. J. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.521200 · Cited by 423
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
Nanoparticle Technologies for Cancer Therapy
Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_2 · Cited by 364
Prevarskaya, N., Zhang, L., & Barritt, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.05.006 · Cited by 355
Ligand-installed nanocarriers toward precision therapy
Mi, P., Cabral, H., & Kataoka, K. (2020) · Advanced Materials · doi:10.1002/adma.201902604 · Cited by 350
Batrakova, E. V., Gendelman, H. E., & Kabanov, A. V. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.559457 · Cited by 323
Recent Advances in miRNA Delivery Systems
Dasgupta, I., & Chatterjee, A. (2021) · Methods and Protocols · doi:10.3390/mps4010010 · Cited by 307
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E., & de Groot, D. J. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.006 · Cited by 292
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma
Reid, G., Pel, M. E., Kirschner, M. B., Cheng, Y. Y., Mugridge, N., Weiss, J., Williams, M., Wright, C., Edelman, J. J. B., Vallely, M. P., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt412 · Cited by 275
Self-citationMacDiarmid, J. A., Amaro-Mugridge, N. B., Madrid-Weiss, J., Sedliarou, I., Wetzel, S., Kochar, K., Brahmbhatt, V. N., Phillips, L., Pattison, S. T., Petti, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1547 · Cited by 272
Self-citationJain, K. K. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6966-1 · Cited by 264
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Killing cancer cells by targeted drug-carrying phage nanomedicines
Bar, H., Yacoby, I., & Benhar, I. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-37 · Cited by 149
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Nicolini, F., Bocchini, M., Bronte, G., Delmonte, A., Guidoboni, M., Crinò, L., & Mazza, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01519 · Cited by 83
Metadata
- Authors
- MacDiarmid, J. A., Mugridge, N. B., Weiss, J. C., Phillips, L., Burn, A. L., Paulin, R. P., Haasdyk, J. E., Dickson, K.-A., Brahmbhatt, V. N., Pattison, S. T., James, A. C., Al Bakri, G., Straw, R. C., Stillman, B., Graham, R. M., & Brahmbhatt, H.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2007-05
- Volume
- 11
- Issue
- 5
- Pages
- 431-445
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2036254354
- Cited by
- 307
- References
- 42
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.